Last update 31 May 2025

Nesvacumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ang2 antibody, Nesvacumab (USAN), REGN-910
+ [1]
Target
Action
inhibitors
Mechanism
Ang2 inhibitors(Angiopoietin-2 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10395Nesvacumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic macular oedemaPhase 1
United States
01 Nov 2014
Wet age-related macular degenerationPhase 1
United States
01 Nov 2014
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Jan 2011
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Jan 2011
Advanced Malignant Solid NeoplasmPhase 1
Canada
01 Jan 2011
Advanced Malignant Solid NeoplasmPhase 1
Canada
01 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
302
Low dose combination (nesvacumab+aflibercept 3 mg:2 mg)
utdffiubds(qofbsoaknc) = eclduhxzci smhcurfyml (zygskvfnzz )
Negative
01 Jul 2018
High dose combination (nesvacumab+aflibercept 6 mg:2 mg)
utdffiubds(qofbsoaknc) = hldusqprwz smhcurfyml (zygskvfnzz )
Phase 1
-
rqamotgqwg(boneisjllq) = 2 patients [10%]; unrelated to study drug/procedure fanecwfvgx (lpgphexsod )
Positive
16 Oct 2016
Phase 1
47
ndplhvguun(whqnikqpik) = qabxrgdjyx uvwvfspxtg (ilymoozdbn )
Positive
15 Mar 2016
Phase 1
37
xggcyybcjj(dvrscyxgks) = Most common G1/2 treatment-related adverse events (TRAEs) were fatigue 7(19%), peripheral edema 6(17%), diarrhea 5(14%), abdominal distension 4(11%), and decreased appetite 4(11%) tirrybxybe (lndcddtjsc )
-
20 May 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free